Olympus: Experiencing Slower Growth, Cost Overruns And FDA Scrutiny (OCPNF)

romaset/iStock via Getty Images Investment thesis Olympus (OTCPK:OCPNF) is experiencing slower-than-anticipated growth and is experiencing reputational risk with the FDA over the manufacturing of its core endoscope business. We have concerns over the quality of management and believe the upcoming growth trajectory is lower than current consensus forecasts. We rate the shares as a Sell….

Read More